$ZIOP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ZIOPHARM ONCOLOGY INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ZIOPHARM ONCOLOGY INC. Get notifications about new insider transactions in ZIOPHARM ONCOLOGY INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Payment of Exercise | F | 0.00 | 2,339 | 0 | 106,525 | 108.9 K to 106.5 K (-2.15 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 18,818 | 0 | 108,864 | 90 K to 108.9 K (+20.90 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 18,818 | 0 | 294,976 | 276.2 K to 295 K (+6.81 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 4.34 | 25,000 | 108,500 | 25,000 | |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Option Exercise | A | 4.34 | 150,000 | 651,000 | 150,000 | |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Payment of Exercise | F | 4.34 | 7,193 | 31,218 | 45,594 | 52.8 K to 45.6 K (-13.63 %) |
Jan 03 2014 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 18,818 | 0 | 78,941 | 60.1 K to 78.9 K (+31.30 %) |
Oct 31 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 3.50 | 2,857,143 | 10,000,001 | 16,390,305 | 13.5 M to 16.4 M (+21.11 %) |
Jun 28 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | Lafond Kevin G | Vice Pres., Treasur ... | Option Exercise | A | 2.30 | 82,500 | 189,750 | 82,500 | |
Jun 28 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Option Exercise | A | 2.30 | 230,000 | 529,000 | 230,000 | |
Jun 28 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | A | 2.30 | 330,000 | 759,000 | 330,000 | |
May 14 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | Amello Jason | Executive Vice Pres ... | Payment of Exercise | F | 1.65 | 2,623 | 4,328 | 22,377 | 25 K to 22.4 K (-10.49 %) |
Feb 25 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Payment of Exercise | F | 4.50 | 5,400 | 24,300 | 52,787 | 58.2 K to 52.8 K (-9.28 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | Amello Jason | Executive Vice Pres ... | Option Exercise | A | 4.16 | 150,000 | 624,000 | 150,000 | |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | Youssoufian Hagop | President of R&D an ... | Option Exercise | A | 4.16 | 180,000 | 748,800 | 180,000 | |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | Youssoufian Hagop | President of R&D an ... | Payment of Exercise | F | 4.21 | 6,919 | 29,129 | 92,721 | 99.6 K to 92.7 K (-6.94 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Payment of Exercise | F | 4.21 | 1,904 | 8,016 | 176,886 | 178.8 K to 176.9 K (-1.06 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 17,546 | 0 | 178,790 | 161.2 K to 178.8 K (+10.88 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.00 | 17,546 | 0 | 252,760 | 235.2 K to 252.8 K (+7.46 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | A | 4.16 | 300,000 | 1,248,000 | 300,000 | |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 4.16 | 21,475 | 89,336 | 524,776 | 546.3 K to 524.8 K (-3.93 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 4.21 | 14,715 | 61,950 | 546,251 | 561 K to 546.3 K (-2.62 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 17,546 | 0 | 90,046 | 72.5 K to 90 K (+24.20 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Payment of Exercise | F | 4.21 | 1,465 | 6,168 | 276,158 | 277.6 K to 276.2 K (-0.53 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 17,546 | 0 | 277,623 | 260.1 K to 277.6 K (+6.75 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Option Exercise | F | 4.21 | 4,909 | 20,667 | 0 | |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Option Exercise | A | 4.16 | 150,000 | 624,000 | 150,000 | |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Payment of Exercise | F | 4.21 | 2,284 | 9,616 | 58,187 | 60.5 K to 58.2 K (-3.78 %) |
Jan 03 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 4.16 | 25,000 | 104,000 | 25,000 | |
Jan 02 2013 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 17,546 | 0 | 60,123 | 42.6 K to 60.1 K (+41.21 %) |
Nov 09 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 0.00 | 3,636,926 | 0 | 13,533,162 | 9.9 M to 13.5 M (+36.75 %) |
Jun 01 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | X | 3.93 | 35,566 | 139,774 | 0 | |
Jun 01 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Sell | J | 5.02 | 27,844 | 139,777 | 161,244 | 189.1 K to 161.2 K (-14.73 %) |
Jun 01 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Buy | X | 3.93 | 35,566 | 139,774 | 189,088 | 153.5 K to 189.1 K (+23.17 %) |
Jun 22 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | Amello Jason | Executive Vice Pres ... | Option Exercise | A | 4.50 | 200,000 | 900,000 | 200,000 | |
Jun 01 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | X | 3.93 | 20,767 | 81,614 | 0 | |
Jun 01 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Sell | J | 5.02 | 16,258 | 81,615 | 235,214 | 251.5 K to 235.2 K (-6.47 %) |
Jun 01 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Buy | X | 3.93 | 20,767 | 81,614 | 251,472 | 230.7 K to 251.5 K (+9.00 %) |
May 10 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | Amello Jason | Executive Vice Pres ... | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Feb 22 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Grant | A | 0.00 | 43,802 | 0 | 65,380 | 21.6 K to 65.4 K (+202.99 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 17,577 | 0 | 260,077 | 242.5 K to 260.1 K (+7.25 %) |
Jan 23 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 5.20 | 1,923,075 | 9,999,990 | 9,896,236 | 8 M to 9.9 M (+24.12 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | Youssoufian Hagop | Executive VP, CMO | Grant | A | 0.00 | 65,380 | 0 | 115,380 | 50 K to 115.4 K (+130.76 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 4.41 | 21,475 | 94,705 | 560,516 | 582 K to 560.5 K (-3.69 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Grant | A | 0.00 | 102,781 | 0 | 581,991 | 479.2 K to 582 K (+21.45 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 17,577 | 0 | 153,522 | 135.9 K to 153.5 K (+12.93 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | A | 4.41 | 25,000 | 110,250 | 25,000 | |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Option Exercise | A | 4.41 | 25,000 | 110,250 | 25,000 | |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 4.41 | 25,000 | 110,250 | 25,000 | |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, CLO, and Secre ... | Grant | A | 0.00 | 21,578 | 0 | 21,578 | 0 to 21.6 K |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Payment of Exercise | F | 4.41 | 7,908 | 34,874 | 211,239 | 219.1 K to 211.2 K (-3.61 %) |
Jan 04 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Grant | A | 0.00 | 65,380 | 0 | 219,147 | 153.8 K to 219.1 K (+42.52 %) |
Jan 03 2012 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 17,577 | 0 | 42,577 | 25 K to 42.6 K (+70.31 %) |
Sep 06 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | BELBEL CAESAR J | EVP, Chief Legal Of ... | Option Exercise | A | 5.17 | 200,000 | 1,034,000 | 200,000 | |
Aug 25 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.99 | 38,294 | 191,087 | 1,346,462 | 1.3 M to 1.3 M (+2.93 %) |
Aug 22 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.91 | 110,792 | 543,989 | 1,308,168 | 1.2 M to 1.3 M (+9.25 %) |
Aug 22 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.91 | 197,376 | 969,116 | 1,197,376 | 1000 K to 1.2 M (+19.74 %) |
Aug 22 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.95 | 153,478 | 759,716 | 1,000,000 | 846.5 K to 1000 K (+18.13 %) |
Aug 11 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Buy | P | 5.19 | 5,000 | 25,926 | 72,500 | 67.5 K to 72.5 K (+7.41 %) |
Aug 09 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 5.13 | 285,518 | 1,464,707 | 846,522 | 561 K to 846.5 K (+50.89 %) |
Aug 09 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.58 | 444,892 | 2,037,605 | 561,004 | 116.1 K to 561 K (+383.16 %) |
Aug 09 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.65 | 116,112 | 539,921 | 116,112 | 0 to 116.1 K |
Jul 18 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | Youssoufian Hagop | Executive VP, CMO | Option Exercise | D | 5.89 | 250,000 | 1,472,500 | 250,000 | |
Jul 18 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | Youssoufian Hagop | Executive VP, CMO | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
May 26 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Sell | S | 6.53 | 15,000 | 97,950 | 135,945 | 150.9 K to 135.9 K (-9.94 %) |
May 11 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Sell | S | 6.57 | 15,000 | 98,615 | 52,500 | 67.5 K to 52.5 K (-22.22 %) |
Feb 07 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 5.75 | 1,910,000 | 10,982,500 | 7,973,161 | 6.1 M to 8 M (+31.50 %) |
Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | A | 5.21 | 25,000 | 130,250 | 25,000 | |
Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 0.00 | 3,636,926 | 0 | 6,063,161 | 2.4 M to 6.1 M (+149.90 %) |
Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Buy | P | 4.80 | 2,426,235 | 11,645,928 | 2,426,235 | 0 to 2.4 M |
Jan 14 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Jan 11 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 5.14 | 15,190 | 78,077 | 479,510 | 494.7 K to 479.5 K (-3.07 %) |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | A | 4.77 | 30,000 | 143,100 | 30,000 | |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 4.77 | 30,000 | 143,100 | 30,000 | |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Option Exercise | A | 4.77 | 30,000 | 143,100 | 30,000 | |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Option Exercise | A | 4.77 | 30,000 | 143,100 | 30,000 | |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Option Exercise | A | 4.77 | 100,000 | 477,000 | 100,000 | |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Payment of Exercise | F | 4.77 | 7,908 | 37,721 | 153,767 | 161.7 K to 153.8 K (-4.89 %) |
Jan 04 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | A | 4.77 | 30,000 | 143,100 | 30,000 | |
Jan 03 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | D | 4.77 | 150,000 | 715,500 | 150,000 | |
Jan 03 2011 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 4.77 | 21,475 | 102,436 | 494,700 | 516.2 K to 494.7 K (-4.16 %) |
Sep 24 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 3.95 | 128,850 | 508,958 | 516,175 | 645 K to 516.2 K (-19.98 %) |
Sep 24 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Payment of Exercise | F | 3.95 | 47,450 | 187,428 | 161,675 | 209.1 K to 161.7 K (-22.69 %) |
Apr 19 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | J | 4.02 | 29,898 | 120,190 | 29,898 | |
Apr 06 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | ABERCROMBIE GEORGE B | Director | Option Exercise | A | 5.36 | 25,000 | 134,000 | 25,000 | |
Apr 06 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | ABERCROMBIE GEORGE B | Director | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Apr 02 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | A | 5.09 | 15,000 | 76,350 | 15,000 | |
Apr 02 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.00 | 15,000 | 0 | 230,705 | 215.7 K to 230.7 K (+6.95 %) |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Option Exercise | A | 5.09 | 15,000 | 76,350 | 15,000 | |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 15,000 | 0 | 242,500 | 227.5 K to 242.5 K (+6.59 %) |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Option Exercise | A | 5.09 | 15,000 | 76,350 | 15,000 | |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Grant | A | 0.00 | 15,000 | 0 | 67,500 | 52.5 K to 67.5 K (+28.57 %) |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 5.09 | 15,000 | 76,350 | 15,000 | |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Grant | A | 0.00 | 15,000 | 0 | 67,500 | 52.5 K to 67.5 K (+28.57 %) |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Option Exercise | A | 5.09 | 15,000 | 76,350 | 15,000 | |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 15,000 | 0 | 67,500 | 52.5 K to 67.5 K (+28.57 %) |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | A | 5.09 | 15,000 | 76,350 | 15,000 | |
Apr 01 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 15,000 | 0 | 150,945 | 135.9 K to 150.9 K (+11.03 %) |
Jan 12 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 3.10 | 12,650 | 39,215 | 645,025 | 657.7 K to 645 K (-1.92 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Option Exercise | A | 2.85 | 7,500 | 21,375 | 7,500 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Grant | A | 0.00 | 7,500 | 0 | 52,500 | 45 K to 52.5 K (+16.67 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | A | 2.85 | 7,500 | 21,375 | 7,500 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.00 | 7,500 | 0 | 215,705 | 208.2 K to 215.7 K (+3.60 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Option Exercise | A | 2.85 | 7,500 | 21,375 | 7,500 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 7,500 | 0 | 227,500 | 220 K to 227.5 K (+3.41 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | A | 2.85 | 7,500 | 21,375 | 7,500 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 7,500 | 0 | 135,945 | 128.4 K to 135.9 K (+5.84 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 2.85 | 7,500 | 21,375 | 7,500 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Grant | A | 0.00 | 7,500 | 0 | 52,500 | 45 K to 52.5 K (+16.67 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Option Exercise | A | 2.85 | 7,500 | 21,375 | 7,500 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 7,500 | 0 | 52,500 | 45 K to 52.5 K (+16.67 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | A | 2.85 | 150,000 | 427,500 | 150,000 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Grant | A | 0.00 | 150,000 | 0 | 657,675 | 507.7 K to 657.7 K (+29.55 %) |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Option Exercise | A | 2.85 | 50,000 | 142,500 | 50,000 | |
Jan 05 2010 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Grant | A | 0.00 | 50,000 | 0 | 209,125 | 159.1 K to 209.1 K (+31.42 %) |
Dec 11 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Option Exercise | P | 4.02 | 87,500 | 351,750 | 87,500 | |
Dec 11 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Buy | P | 3.10 | 175,000 | 542,500 | 220,000 | 45 K to 220 K (+388.89 %) |
Dec 11 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | P | 4.02 | 25,000 | 100,500 | 25,000 | |
Dec 11 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Buy | P | 3.10 | 50,000 | 155,000 | 208,205 | 158.2 K to 208.2 K (+31.60 %) |
Dec 10 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | ESSEX WOODLANDS HEALTH VENTURE ... | 10% Owner | Option Exercise | P | 4.02 | 64,500 | 259,290 | 64,500 | |
Dec 10 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | ESSEX WOODLANDS HEALTH VENTURE ... | 10% Owner | Option Exercise | P | 2.04 | 328,766 | 670,683 | 328,766 | |
Dec 10 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | ESSEX WOODLANDS HEALTH VENTURE ... | 10% Owner | Buy | P | 3.10 | 129,000 | 399,900 | 2,371,642 | 2.2 M to 2.4 M (+5.75 %) |
Dec 10 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | ESSEX WOODLANDS HEALTH VENTURE ... | 10% Owner | Buy | P | 1.83 | 328,766 | 599,998 | 2,242,642 | 1.9 M to 2.2 M (+17.18 %) |
Dec 07 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Payment of Exercise | F | 3.66 | 47,625 | 174,308 | 507,375 | 555 K to 507.4 K (-8.58 %) |
Dec 07 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Payment of Exercise | F | 3.66 | 15,875 | 58,103 | 159,125 | 175 K to 159.1 K (-9.07 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.00 | 30,000 | 0 | 128,445 | 98.4 K to 128.4 K (+30.47 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Grant | A | 0.00 | 300,000 | 0 | 555,000 | 255 K to 555 K (+117.65 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Grant | A | 0.00 | 100,000 | 0 | 175,000 | 75 K to 175 K (+133.33 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
Sep 24 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.00 | 30,000 | 0 | 158,205 | 128.2 K to 158.2 K (+23.40 %) |
Sep 17 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | J | 2.04 | 40,298 | 82,208 | 40,298 | |
Sep 17 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | P | 2.04 | 50,000 | 102,000 | 50,000 | |
Sep 17 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Buy | P | 1.83 | 50,000 | 91,250 | 128,205 | 78.2 K to 128.2 K (+63.93 %) |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Option Exercise | A | 0.70 | 15,000 | 10,500 | 15,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Option Exercise | A | 0.70 | 15,000 | 10,500 | 15,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Option Exercise | A | 0.70 | 15,000 | 10,500 | 15,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Option Exercise | A | 0.70 | 15,000 | 10,500 | 15,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Option Exercise | A | 0.70 | 15,000 | 10,500 | 15,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Option Exercise | A | 0.70 | 15,000 | 10,500 | 15,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | BAGLEY RICHARD E | President, COO & Tr ... | Option Exercise | A | 0.70 | 100,000 | 70,000 | 100,000 | |
May 15 2009 | ZIOP | ZIOPHARM ONCOLOGY ... | LEWIS JONATHAN | CEO | Option Exercise | A | 0.70 | 100,000 | 70,000 | 100,000 | |
Dec 05 2008 | ZIOP | ZIOPHARM ONCOLOGY ... | CANNON JAMES ANTHONY | Director | Grant | A | 0.83 | 15,000 | 12,450 | 15,000 | 0 to 15 K |
Dec 05 2008 | ZIOP | ZIOPHARM ONCOLOGY ... | WEISER MICHAEL | Director | Grant | A | 0.83 | 15,000 | 12,450 | 98,445 | 83.4 K to 98.4 K (+17.98 %) |
Dec 05 2008 | ZIOP | ZIOPHARM ONCOLOGY ... | BRENNAN MURRAY | Director | Grant | A | 0.83 | 15,000 | 12,450 | 15,000 | 0 to 15 K |
Dec 05 2008 | ZIOP | ZIOPHARM ONCOLOGY ... | MCINERNEY TIMOTHY | Director | Grant | A | 0.83 | 15,000 | 12,450 | 78,205 | 63.2 K to 78.2 K (+23.73 %) |
Dec 05 2008 | ZIOP | ZIOPHARM ONCOLOGY ... | FRAGIN GARY S | Director | Grant | A | 0.83 | 15,000 | 12,450 | 15,000 | 0 to 15 K |
Dec 05 2008 | ZIOP | ZIOPHARM ONCOLOGY ... | Fowler Wyche | Director | Grant | A | 0.83 | 15,000 | 12,450 | 15,000 | 0 to 15 K |